--- title: "Is It Time To Reassess Abivax (ENXTPA:ABVX) After The Recent Share Price Pullback" type: "News" locale: "en" url: "https://longbridge.com/en/news/280921175.md" description: "ABIVAX Société Anonyme's stock has recently pulled back, closing at €89.20 after an 18.5% decline over the past week. Despite this, the company has shown strong long-term gains. A Discounted Cash Flow analysis suggests the stock is undervalued by 87.0%, with an estimated intrinsic value of €685.04 per share. However, its Price-to-Book ratio of 15.52x is significantly higher than industry averages, indicating a richer valuation compared to peers. Investors are encouraged to consider different valuation methods and narratives for a comprehensive understanding of the company's worth." datetime: "2026-03-29T21:43:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280921175.md) - [en](https://longbridge.com/en/news/280921175.md) - [zh-HK](https://longbridge.com/zh-HK/news/280921175.md) --- # Is It Time To Reassess Abivax (ENXTPA:ABVX) After The Recent Share Price Pullback - If you are wondering whether ABIVAX Société Anonyme is priced attractively right now, the starting point is to compare what you pay today with what the business could be worth under different valuation lenses. - The stock last closed at €89.20, after a 7 day return of an 18.5% decline and a 30 day return of a 13.1% decline, set against a very large 1 year gain and an 11.8x return over 3 years. - Recent attention on ABIVAX Société Anonyme has been shaped by ongoing coverage of its position in the pharmaceuticals and biotech space and investor interest in companies listed on Euronext Paris. This context helps explain why short term pullbacks sit alongside very strong multi year returns. - The company currently has a valuation score of 2 out of 6. Next you will see how different methods such as multiples and discounted cash flow attempt to frame fair value, and then finish with a way of looking at valuation that can give you an even fuller picture. ABIVAX Société Anonyme scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. ### Approach 1: ABIVAX Société Anonyme Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model estimates what a company could be worth by projecting its future cash flows and then discounting those amounts back to today using a required rate of return. For ABIVAX Société Anonyme, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in €. The latest twelve month free cash flow is a loss of €161.4m. Analyst and extrapolated estimates in the model show free cash flow staying negative in the mid term, then turning positive, with a projected free cash flow of €3,474.6m in 2035. After discounting the projected cash flows, the model arrives at an estimated intrinsic value of €685.04 per share. Compared with the recent share price of €89.20, this implies the stock is about 87.0% undervalued according to this DCF output. This is a cash flow heavy story, so for investors who rely on DCF work, ABIVAX Société Anonyme screens as materially cheap on these inputs. **Result: UNDERVALUED** Our Discounted Cash Flow (DCF) analysis suggests ABIVAX Société Anonyme is undervalued by 87.0%. Track this in your watchlist or portfolio, or discover 236 more high quality undervalued stocks. ABVX Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for ABIVAX Société Anonyme. ### Approach 2: ABIVAX Société Anonyme Price vs Book For companies where earnings can be volatile or negative, the P/B ratio can be a useful way to think about value because it compares the market price with the accounting value of net assets. In general, higher growth expectations and lower perceived risk can support a higher “normal” valuation multiple, while lower growth or higher risk tend to support a lower one. ABIVAX Société Anonyme currently trades on a P/B ratio of 15.52x. That sits well above the Biotechs industry average of 3.43x and also above the peer group average of 5.09x, so on simple comparisons the shares are pricing in a much richer valuation than many sector peers. Simply Wall St’s Fair Ratio metric goes a step further by estimating what a suitable P/B might be for ABIVAX Société Anonyme given factors such as its earnings profile, growth outlook, profit margins, size and company specific risks. This tailored yardstick can be more informative than broad industry or peer comparisons because it aligns the expected multiple with the company’s own characteristics. In this case, the Fair Ratio is not available, so it is not possible to say whether the current 15.52x P/B looks high, low or about right relative to that proprietary benchmark. **Result: ABOUT RIGHT** ENXTPA:ABVX P/B Ratio as at Mar 2026 P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 96 top founder-led companies. ### Upgrade Your Decision Making: Choose your ABIVAX Société Anonyme Narrative Earlier it was mentioned that there is an even better way to understand valuation, and on Simply Wall St this takes the form of Narratives. You set out your story for ABIVAX Société Anonyme, link that story to assumptions for future revenue, earnings and margins, and let the platform turn it into a forecast and fair value that can be compared with the current price. This is updated automatically when fresh news or earnings arrive. On the Community page, you might see one investor building a cautious Narrative with fair value near €101.40, while another uses a more optimistic Narrative closer to €179.70. This gives you a clear, side by side sense of how different views translate into different estimates of what the shares could be worth and when the gap between price and fair value might justify action for your own plan. Do you think there's more to the story for ABIVAX Société Anonyme? Head over to our Community to see what others are saying! ENXTPA:ABVX 1-Year Stock Price Chart _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md) - [Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study](https://longbridge.com/en/news/287280796.md) - [Black Diamond reports Phase 2 silevertinib mPFS 15.2 months in frontline EGFR-mutant NSCLC](https://longbridge.com/en/news/287274011.md) - [Nuvalent to present pivotal ALKOVE-1 neladalkib data in ALK-positive NSCLC at ASCO 2026](https://longbridge.com/en/news/287275055.md) - [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)